|Day Low/High||59.74 / 60.00|
|52 Wk Low/High||52.26 / 101.80|
Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.
There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.
The days of rapid growth are far behind Japan. So can these Tokyo listings deliver as much bite as the FANGs?
The Nikkei 225 closed with a gain for 2016, making a run of five consecutive higher year-end closes -- the first since the 1990 bubble.